• Azitra posted a net loss of $3.93 million for the quarter ended March 31, 2026, widening 28% from a year earlier.
• Operating loss widened to $3.93 million, driven by total operating expenses rising 27% to $3.93 million.
• General and administrative costs climbed 28% to $2.37 million, primarily due to a roughly $624,000 write-off of deferred patent costs.
• Research and development spending increased 25% to $1.56 million, with higher ATR-01 and ATR-04 costs partly offset by lower ATR-12 spending.
• Cash and cash equivalents totaled about $10.1 million as of March 31, 2026, while management said cash on hand will not be sufficient to fund its operating plan over the next 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001701478-26-000028), on May 13, 2026, and is solely responsible for the information contained therein.